ArticleFrontiers in neurology2025
Safety and feasibility of dual antiplatelet therapy termination guided by angioscopic findings 6 months after flow diverter placement.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Flow diverters (FDs) are commonly used to treat intracranial aneurysms with wide necks. Dual antiplatelet therapy (DAPT) is essential during the perioperative period to prevent thrombosis; however, it increases the risk of hemorrhagic complications, warranting early discontinuation when feasible. Neointimal formation over FD is crucial for safe DAPT discontinuation. This study aimed to directly visualize neointimal coverage 6 months after FD placement using angioscopy and evaluate the safety of DAPT termination. Methods: Eight consecutive patients undergoing FD placement for internal carotid artery aneurysms between April 2022 and February 2024 were included in the prospective evaluation. Angioscopy was conducted at 6 months (±1 month) after FD placement to assess neointimal formation, which was graded 0-3 based on coverage (grade 0: no neointima; grade 1: slight; grade 2: translucent coverage; grade 3: full opaque coverage). Cone-beam computed tomography (CT) was concurrently performed to evaluate radiolucent gaps as indirect evidence of neointima formation. DAPT was discontinued if the neointimal coverage was graded ≥1, followed by the monitoring of ischemic events for 1 month. Results: The mean age of patients was 60.5 (49-81) years, and the mean aneurysm diameter was 7.7 mm (5.1-14.6 mm). Angioscopic neointimal grading was ≥1 in all cases, while cone-beam CT revealed no radiolucent gaps in one case. No procedural complications were observed. Following DAPT discontinuation, all the patients were administered single antiplatelet therapy, with no ischemic events observed within 1 month. Conclusion: Angioscopy reliably confirmed neointimal coverage 6 months after FD placement, suggesting the potential for safe DAPT discontinuation. The findings underscore the superiority of angioscopy over cone-beam CT in identifying thin neointima. Further studies involving larger cohorts and applying advanced imaging technologies are required to optimize post-FD antiplatelet therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.